{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T19:53:31Z","timestamp":1772740411435,"version":"3.50.1"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND AND OBJECTIVE:<\/jats:title><jats:p>In 2006, routine 2-dose varicella vaccination for children was recommended to improve control of varicella. We assessed the safety of second-dose varicella vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>We identified second-dose single-antigen varicella vaccine reports in the Vaccine Adverse Event Reporting System during 2006 to 2014 among children aged 4 to 18 years. We analyzed reports by age group (4\u20136 and 7\u201318 years), sex, serious or nonserious status, most common adverse events (AEs), and whether other vaccines were administered concomitantly with varicella vaccine. We reviewed serious reports of selected AEs and conducted empirical Bayesian data mining to detect disproportional reporting of AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>We identified 14\u2009641 Vaccine Adverse Event Reporting System reports after second-dose varicella vaccination, with 494 (3%) classified as serious. Among nonserious reports, injection site reactions were most common (48% of children aged 4\u20136 years, 38% of children aged 7\u201318 years). The most common AEs among serious reports were pyrexia (31%) for children aged 4 to 6 years and headache (28%) and vomiting (27%) for children aged 7 to 18 years. Serious reports of selected AEs included anaphylaxis (83), meningitis (5), encephalitis (16), cellulitis (52), varicella (6), herpes zoster (6), and deaths (7). One immunosuppressed adolescent was reported with vaccine-strain herpes zoster. Only previously known AEs were reported more frequently after second-dose varicella vaccination compared with other vaccines.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>We identified no new or unexpected safety concerns for second-dose varicella vaccination. Robust safety monitoring remains an important component of the national varicella vaccination program.<\/jats:p><\/jats:sec>","DOI":"10.1542\/peds.2016-2536","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T10:10:11Z","timestamp":1486462211000},"source":"Crossref","is-referenced-by-count":7,"title":["Safety of Second-Dose Single-Antigen Varicella Vaccine"],"prefix":"10.1542","volume":"139","author":[{"given":"John R.","family":"Su","sequence":"first","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanie","family":"Leroy","sequence":"additional","affiliation":[{"name":"School Health Branch, Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige W.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penina","family":"Haber","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Marin","sequence":"additional","affiliation":[{"name":"Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Leung","sequence":"additional","affiliation":[{"name":"Epidemiology Branch, Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily Jane","family":"Woo","sequence":"additional","affiliation":[{"name":"Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Springs, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom T.","family":"Shimabukuro","sequence":"additional","affiliation":[{"name":"Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"2021120907440270800_B1","unstructured":"Food and Drug Administration. Varivax prescribing information. Published 1995. Available at: www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM142812.pdf. Accessed November 14, 2016"},{"key":"2021120907440270800_B2","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1086\/522156","article-title":"Changing varicella epidemiology in active surveillance sites--United States, 1995-2005.","volume":"197","author":"Guris","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"2021120907440270800_B3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa042271","article-title":"Decline in mortality due to varicella after implementation of varicella vaccination in the United States.","volume":"352","author":"Nguyen","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"2021120907440270800_B4","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995-2000.","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"issue":"3","key":"2021120907440270800_B5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2008-0567","article-title":"Varicella prevention in the United States: a review of successes and challenges.","volume":"122","author":"Marin","year":"2008","journal-title":"Pediatrics"},{"issue":"6","key":"2021120907440270800_B6","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2005-2085","article-title":"One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?","volume":"117","author":"Lopez","year":"2006","journal-title":"Pediatrics"},{"key":"2021120907440270800_B7","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"22","key":"2021120907440270800_B8","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy trial in healthy children.","volume":"310","author":"Weibel","year":"1984","journal-title":"N Engl J Med"},{"key":"2021120907440270800_B9","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1086\/522161","article-title":"Safety of varicella vaccine after licensure in the United States: experience from reports to the Vaccine Adverse Event Reporting System, 1995-2005.","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"issue":"1","key":"2021120907440270800_B10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00006454-199601000-00011","article-title":"Safety and immunogenicity of one vs. two injections of Oka\/Merck varicella vaccine in healthy children.","volume":"15","author":"Ngai","year":"1996","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120907440270800_B11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2021120907440270800_B12","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities. Available at: www.meddra.org. Accessed January 19, 2016"},{"key":"2021120907440270800_B13","unstructured":"Food and Drug Administration. Code of Federal Regulations Title 21. Published 2015. Available at: www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=310.305. Accessed January 19, 2016"},{"issue":"1","key":"2021120907440270800_B14","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-0665","article-title":"Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures.","volume":"126","author":"Klein","year":"2010","journal-title":"Pediatrics"},{"issue":"12","key":"2021120907440270800_B15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamapediatrics.2013.2745","article-title":"Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children.","volume":"167","author":"Rowhani-Rahbar","year":"2013","journal-title":"JAMA Pediatr"},{"key":"2021120907440270800_B16","first-page":"239","volume-title":"Varicella Virus Vaccine. Adverse effects of Vaccines: Evidence and Causality","author":"Institute of Medicine","year":"2012"},{"issue":"3-4","key":"2021120907440270800_B17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI).","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"key":"2021120907440270800_B18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system.","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"6","key":"2021120907440270800_B19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database.","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"10","key":"2021120907440270800_B20","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.vaccine.2004.08.040","article-title":"Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan.","volume":"23","author":"Ozaki","year":"2005","journal-title":"Vaccine"},{"issue":"2","key":"2021120907440270800_B21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0091-6749(97)70108-8","article-title":"IgE-mediated systemic reactions to gelatin included in the varicella vaccine.","volume":"99","author":"Sakaguchi","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2021120907440270800_B22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/infdis\/jiq066","article-title":"Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine.","volume":"203","author":"Pahud","year":"2011","journal-title":"J Infect Dis"},{"key":"2021120907440270800_B23","unstructured":"Centers for Disease Control and Prevention. Adverse events following vaccination. Published 2015. Available at: www.cdc.gov\/vaccines\/pubs\/pinkbook\/mening.html#reactions. Accessed February 1, 2016"},{"issue":"12","key":"2021120907440270800_B24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s004150050546","article-title":"Combined acute disseminated encephalomyelitis and acute motor axonal neuropathy after vaccination for hepatitis A and infection with Campylobacter jejuni.","volume":"246","author":"Huber","year":"1999","journal-title":"J Neurol"},{"issue":"7002","key":"2021120907440270800_B25","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.311.7002.422a","article-title":"Transverse myelitis after measles, mumps, and rubella vaccine.","volume":"311","author":"Joyce","year":"1995","journal-title":"BMJ"},{"issue":"22","key":"2021120907440270800_B26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM197011262832208","article-title":"Meningoencephalitis following an influenza vaccination.","volume":"283","author":"Rosenberg","year":"1970","journal-title":"N Engl J Med"},{"issue":"4","key":"2021120907440270800_B27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-2633","article-title":"Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child.","volume":"125","author":"Chouliaras","year":"2010","journal-title":"Pediatrics"},{"issue":"10","key":"2021120907440270800_B28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine.","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"issue":"8","key":"2021120907440270800_B29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/INF.0b013e31816fc323","article-title":"Large injection site reactions after a second dose of varicella vaccine.","volume":"27","author":"Walter","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"2021120907440270800_B30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/pch\/14.4.245","article-title":"Vaccination site reaction or bacterial cellulitis?","volume":"14","author":"Lapphra","year":"2009","journal-title":"Paediatr Child Health"},{"key":"2021120907440270800_B31","unstructured":"Centers for Disease Control and Prevention. General recommendations on immunization. Published 2015. Available at: www.cdc.gov\/vaccines\/pubs\/pinkbook\/genrec.html. Accessed February 2, 2016"},{"issue":"1","key":"2021120907440270800_B32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1542\/pir.31.1.38","article-title":"Vaccines in immunocompromised patients.","volume":"31","author":"Tamma","year":"2010","journal-title":"Pediatr Rev"},{"issue":"10","key":"2021120907440270800_B33","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/INF.0000000000000821","article-title":"Impact of the US two-dose varicella vaccination program on the epidemiology of varicella outbreaks: data from nine states, 2005-2012.","volume":"34","author":"Leung","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"27","key":"2021120907440270800_B34","first-page":"577","article-title":"Intussusception among recipients of rotavirus vaccine--United States, 1998-1999.","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"43","key":"2021120907440270800_B35","first-page":"1007","article-title":"Withdrawal of rotavirus vaccine recommendation.","volume":"48","author":"Centers for Disease Control and Prevention (CDC)","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2021120907440270800_B36","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/21645515.2015.1008880","article-title":"Trends in varicella mortality in the United States: data from vital statistics and the national surveillance system.","volume":"11","author":"Leung","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"2021120907440270800_B37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/jpids\/piv044","article-title":"Impact of the maturing varicella vaccination program on varicella and related outcomes in the United States: 1994-2012.","volume":"5","author":"Leung","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2021120907440270800_B38","doi-asserted-by":"crossref","article-title":"Pregnancy registry for varicella-zoster virus-containing vaccines: 18-year summary of pregnancy outcomes.","author":"Willis","DOI":"10.1093\/ofid\/ofu052.756"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2536\/1063643\/peds_20162536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-2536\/1063643\/peds_20162536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T10:01:53Z","timestamp":1719050513000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/139\/3\/e20162536\/53397\/Safety-of-Second-Dose-Single-Antigen-Varicella"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,1]]},"published-print":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-2536","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]},"article-number":"e20162536"}}